McKesson sees flat growth in Medical-Surgical segment
By HME News Staff
Updated 10:05 AM CST, Mon November 10, 2025
IRVING, Texas – McKesson reported revenues of $2.9 billion for its Medical-Surgical Segment for the second quarter of fiscal year 2026, flat to the same period the prior year. Revenues were driven by higher volumes of specialty pharmaceuticals, offset by lower contributions from illness season products and testing. Operating profit for the segment was $220 million and adjusted operating profit was $249 million, a 2% increase, driven by operational efficiencies from cost optimization initiatives, partially offset by lower contributions from illness season products and testing. Overall, McKesson reported revenues of a record high of $103.2 billion, a 10% increase compared to the same period the prior year. It also reported:
- Earnings per diluted share of $8.92 increased $7.05.
- Adjusted earnings per diluted share of $9.86 increased 39%.
- Generated $2.4 billion of cash flow from operations and $2.2 billion of free cash flow.
For its 2026 full-year outlook, McKesson has raised adjusted earnings per diluted share guidance range to $38.85, from the previous range of $38.05 to $38.55. Among its business highlights for the quarter, the company reiterated its plans to spin off its Medical-Surgical segment.
Comments